DELFI Diagnostics Announces Availability of Fragmentome-Based Cancer Monitoring Assay and Collaboration with Immunocore Holdings plc

DELFI Diagnostics, Inc. has announced the availability of the company’s fragmentome-based research use only (RUO) cancer monitoring assay, offering a highly sensitive, inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer. The company has also revealed a new research collaboration with Immunocore Holdings plc, focusing on exploring the use of the DELFI-TF cancer monitoring assay as an early predictor of benefit from treatment with ImmTAC-based therapies. DELFI Diagnostics is developing next-generation, blood-based tests that are accurate, accessible and deliver a new way to help detect cancer.